SSK1 - CAS:2629250-69-5

您当前的位置：

SSK1

目录号 : KM8766 CAS No. : 2629250-69-5 纯度 : 98%

Data Sheet 产品使用指南

SSK1，是一种衰老特异性杀伤化合物，是一种 β-galactosidase 靶向前药，可减轻炎症。SSK1 被溶酶体 β-galactosidase 激活，并通过激活 p38 MAPK 和诱导细胞凋亡 (apoptosis) 选择性杀死衰老细胞。

规格	价格	是否有货
5mg		In-stock
10mg		In-stock
50mg	询价	In-stock
100mg	询价	In-stock

加入购物车大包装询价

Other Forms of Rapamycin:

Kgp-IN-1 hydrochloride In-stock
Ginkgolide A In-stock
Ginkgetin In-stock
VKGILS-NH2 In-stock
7,3',4'-Tri-O-methylluteolin In-stock

KKL Med 的所有产品和服务仅用于科学研究，不能被用于人体，兽医，我们也不向个人提供产品和服务。

生物活性

SSK1, a senescence-specific killing compound, is a β-galactosidase-targeted prodrug attenuates inflammation. SSK1 is activated by lysosomal β-galactosidase and selectively killed senescent cells through the activation of p38 MAPK and induction of apoptosis.

体外研究

SSK1 (0.5 µM; 12-72 hours) activates the phosphorylation levels of both p38 MAPK and MKK3/MKK6 in senescent cells. SSK1 kills senescent cells through the activation of the p38 MAPK signaling pathway. SSK1 is able to induce mitochondrial DNA damage in senescent cells.
SSK1 (0.01-1 µM; 3 days) selectively and potently eliminates β-galactosidase-positive senescent cells within a wide therapeutic window.

Cell Proliferation Assay

Cell Line:	Primary mouse fibroblasts
Concentration:	0.5 µM
Incubation Time:	12 hours, 24 hours, 36 hours, 48 hours, 72 hours
Result:	Both p38 MAPK and MKK3/MKK6 were activated by phosphorylation in senescent cells.

体内研究

SSK1 (0.5 mg/kg; i.p.; two days every week; for four weeks) could eliminate senescent cells and decrease senescence-associated markers in lung-injured mice.
In aged mice (20-month-old), SSK1 (0.5 mg/kg; 3 days every 2 weeks for 8 weeks) effectively clears senescent cells in different tissues, decreases the senescence- and age-associated gene signatures, attenuates low-grade local and systemic inflammation, and restores physical function.

Animal Model:	Mice (3-6-month-old) were subjected to transtracheal injection of Bleomycin
Dosage:	0.5 mg/kg
Administration:	Intraperitoneally injection; two days every week; for four weeks
Result:	SSK1 significantly reduced the percentage of SA-β-gal-positive cells in lung by 3.8-fold compared with that in vehicle-treated lung-injured mice

分子量

788.61

CAS号

2629250-69-5

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

溶解性数据

In Vitro:

DMSO : 200 mg/mL (253.61 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.2681 mL	6.3403 mL	12.6805 mL
5 mM	0.2536 mL	1.2681 mL	2.5361 mL
10 mM	0.1268 mL	0.6340 mL	1.2681 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 5 mg/mL (6.34 mM); Clear solution

此方案可获得 ≥ 5 mg/mL (6.34 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 5 mg/mL (6.34 mM); Clear solution

此方案可获得 ≥ 5 mg/mL (6.34 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。